Nets more than $35 mil. from secondary offering of 2.6 mil. shares at $14.75 per share, Tarrytown, N.Y. company announces Aug. 26. Firm now has over $110 mil. in cash on hand. Offering was managed by Lehman Brothers, Montgomery Securities and Dillon, Read.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth